Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell-surface N-linked galactose residues are specific carbohydrate structures attached to the nitrogen atom of asparagine residues on proteins through N-glycosylation (Varki et al., 2017). These residues typically appear at the terminal or sub-terminal positions of complex oligosaccharide chains and are often masked by sialic acid in healthy physiological states. When terminal sialic acid is removed—a process often associated with cellular aging or pathological conditions—the exposed galactose residues serve as a critical biological signal for the clearance of glycoproteins from circulation via the asialoglycoprotein receptor (ASGPR) located on hepatocytes (Stockert, 1995). In oncology, aberrant glycosylation patterns frequently result in the over-exposure of these galactose residues, which can influence tumor metastasis, cell adhesion, and immune system evasion (Pinho & Reis, 2015). From a therapeutic perspective, these residues are highly significant as they are the primary target for galactose- and N-acetylgalactosamine (GalNAc)-conjugated delivery systems, which exploit the high-capacity endocytic pathway of the liver to deliver RNA interference (RNAi) therapies and other oligonucleotides (D'Souza & Devarajan, 2015). Additionally, experimental strategies involve using neuraminidase enzymes to intentionally expose these residues on tumor cells to enhance their recognition and destruction by the immune system.
Binding to the asialoglycoprotein receptor (ASGPR) to facilitate receptor-mediated endocytosis and hepatic drug delivery, or serving as a recognition site for carbohydrate-binding proteins (lectins) to trigger cellular responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell-surface N-linked galactose residues (N-linked Gal).